Discovery of a potent ROR1 inhibitor using μs-scale MD simulations, wt-metadynamics, and absolute binding free energy calculations

No abstract is available for this paper.

• Publication year

  2025

• Venue

  Journal of Molecular Modeling

• Publication date

  2025-09-25

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s00894-025-06508-3PMID 40996455
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Enhanced sampling simulations to explore himalayan phytochemicals as potential phosphodiesterase-1 inhibitor for neurological disorders.

  2025cited by this paper
• Beyond trial and error: Leveraging advanced software for Therapeutic discovery

  2025cited by this paper
• Exploring treatment options in cancer: tumor treatment strategies

  2024cited by this paper
• Discovery of Novel Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) Inhibitors for Cancer Treatment.

  2024cited by this paper
• Global cancer burden growing, amidst mounting need for services

  2024cited by this paper
• How receptor tyrosine kinase‐like orphan receptor 1 meets its partners in chronic lymphocytic leukemia

  2024cited by this paper
• A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer

  2024cited by this paper
• Identification of potential inhibitors for MAP4K4 in glaucoma using Meta-Dynamics-Based dissociation free energy calculation.

  2024cited by this paper
• A Small Molecule Targeting the Intracellular Tyrosine Kinase Domain of ROR1 (KAN0441571C) Induced Significant Apoptosis of Non-Small Cell Lung Cancer (NSCLC) Cells

  2023cited by this paper
• Small-molecule agents for cancer immunotherapy

  2023cited by this paper
• Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future

  2023cited by this paper
• Identification and validation of a small molecule targeting ROR1 for the treatment of triple negative breast cancer

  2023cited by this paper
• Updating the Definition of Cancer

  2023cited by this paper
• Understanding and targeting resistance mechanisms in cancer

  2023cited by this paper
• Enhancing Hit Discovery in Virtual Screening through Absolute Protein-Ligand Binding Free-Energy Calculations

  2023cited by this paper
• Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma

  2023cited by this paper
• Accurate determination of protein:ligand standard binding free energies from molecular dynamics simulations

  2022cited by this paper
• Microsecond-long simulation reveals the molecular mechanism for the dual inhibition of falcipain-2 and falcipain-3 by antimalarial lead compounds

  2022cited by this paper
• Recent advances in targeting protein kinases and pseudokinases in cancer biology

  2022cited by this paper
• Fedratinib, the first selective JAK2 inhibitor approved for treatment of myelofibrosis – an option beyond ruxolitinib

  2022cited by this paper
• ROR1: an orphan becomes apparent

  2022influential reference
• Looking lively: emerging principles of pseudokinase signaling.

  2022cited by this paper
• High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia

  2022cited by this paper
• A highly accurate metadynamics-based Dissociation Free Energy method to calculate protein–protein and protein–ligand binding potencies

  2022cited by this paper
• Small molecules in targeted cancer therapy: advances, challenges, and future perspectives

  2021cited by this paper
• BFEE2: Automated, Streamlined, and Accurate Absolute Binding Free-Energy Calculations

  2021cited by this paper
• ROR and RYK extracellular region structures suggest that receptor tyrosine kinases have distinct WNT-recognition modes

  2021cited by this paper
• A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1+ CLL cells

  2021cited by this paper
• A narrative review of tumor heterogeneity and challenges to tumor drug therapy

  2021cited by this paper
• Improving Protein-Ligand Docking Results with High-Throughput Molecular Dynamics Simulations

  2020cited by this paper
• Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis

  2020cited by this paper
• Structural Insights into Pseudokinase Domains of Receptor Tyrosine Kinases.

  2020cited by this paper
• ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells

  2020cited by this paper
• Metadynamics as a Postprocessing Method for Virtual Screening with Application to the Pseudokinase Domain of JAK2

  2020cited by this paper
• Drug resistance and combating drug resistance in cancer

  2019cited by this paper
• A ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells

  2019cited by this paper
• Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity

  2019cited by this paper
• Prospects for pharmacological targeting of pseudokinases

  2019cited by this paper
• Avoiding False Positive Conclusions in Molecular Simulation: The Importance of Replicas.

  2018cited by this paper
• Unbinding Dynamics of Non-Nucleoside Inhibitors from HIV-1 Reverse Transcriptase.

  2018cited by this paper
• A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib

  2018cited by this paper
• Free-Energy Landscape of Protein-Ligand Interactions Coupled with Protein Structural Changes.

  2017cited by this paper
• Pseudokinases: update on their functions and evaluation as new drug targets.

  2017cited by this paper
• Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues

  2016cited by this paper
• Clinical potential of pacritinib in the treatment of myelofibrosis

  2015cited by this paper
• Principal component analysis: a method for determining the essential dynamics of proteins.

  2014cited by this paper
• Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments

  2013cited by this paper
• Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking

  2011cited by this paper
• Well-tempered metadynamics: a smoothly converging and tunable free-energy method.

  2008cited by this paper
• CHARMM‐GUI: A web‐based graphical user interface for CHARMM

  2008cited by this paper
• Scalable Algorithms for Molecular Dynamics Simulations on Commodity Clusters

  2006cited by this paper
• Virtual screening: Gliding to success

  2004cited by this paper
• Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.

  2004cited by this paper
• The Protein Data Bank

  2000cited by this paper
• Commodity clusters

  1998cited by this paper
• VMD: visual molecular dynamics.

  1996cited by this paper

• ROR1 protein: a pseudokinase at the crossroads of cancer progression and therapy

  2026cites this paper